<DOC>
	<DOCNO>NCT00378183</DOCNO>
	<brief_summary>The purpose study compare three strategy switch patient schizophrenia schizoaffective disorder atypical antipsychotic , risperdone , unsuccessfully treat another atypical antipsychotic , olanzapine . In second phase study , investigator assess effectiveness behavioral therapy reduce body weight risperdone-treated patient overweight problem diabetes blood sugar .</brief_summary>
	<brief_title>A Study Comparing Three Strategies Switch Patients With Schizophrenia Schizoaffective Disorder Risperidone After Unsuccessful Treatment With Olanzapine .</brief_title>
	<detailed_description>Data regard safety effectiveness different strategy switch subject schizophrenia one antipsychotic medication another rare . Studies examine various switch design , especially regard new atypical antipsychotic agent , suggest either abrupt gradual discontinuation inevitably lead worsening symptom . This study randomize ( patient assign different treatment base chance ) , open-label , parallel group design ass safety effectiveness three strategy discontinue olanzapine start risperidone . The first strategy discontinuation olanzapine day risperidone start . The second strategy involve reduction dose olanzapine one half study entry dose day risperidone start . The reduced dose olanzapine give one week discontinue . In third strategy , dose olanzapine remain unchanged first week , reduce one half study entry dose , end second week discontinue . In three strategy , patient take dose risperidone : 1 mg mouth twice day 3 day , 2 mg twice day next 4 day . Further increase decrease risperidone dose and/or change single daily dose carry end first week . Additionally , 6 week risperidone therapy , patient overweight problem diabetes blood sugar may enter second phase study examines weight loss . In phase , patient randomize receive routine clinical care train weight management behavioral technique continue take risperidone additional 14 week . At end 14 week , total weight loss , change lipid , cholesterol laboratory measure compare two group . The study hypothesis symptom improvement worsen week 14 , measure total score Positive Negative Syndrome Scale ( PANSS ) , differ depend method switch olanzapine risperidone . Safety evaluation incude collection adverse event , clinical laboratory test assessment vital sign . The patient receive oral tablet risperidone 1 2 milligram [ mg ] twice day ( high low dose and/or change single daily dose allow end first week ) duration 6 week phase 1 , 14 week phase 2 study . Olanzapine : none ; half study entry dose 1 week ; study entry dose 1 week , half study entry dose additional week .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Patients DSMIV ( Diagnostic Statistical Manual Mental Disorders , Fourth Edition ) diagnosis schizophrenia schizoaffective disorder Taking stable dose olanzapine least 30 day Have experience acute exacerbation psychotic symptom precede 3 month Either marginal clinical response olanzapine , unacceptable side effect relate weight gain include obesity , diabetes abnormal glucose metabolism Patients history treatment failure , significant adverse event attributable , risperidone , know sensitivity risperidone A history antipsychotic therapy olanzapine 30 day precede randomization Presence serious unstable illness : liver renal insufficiency , significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurological , psychiatric metabolic disturbance Diagnosis substance dependence Pregnant nursing female , lack adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>weight loss</keyword>
	<keyword>behavioral therapy</keyword>
	<keyword>risperidone</keyword>
	<keyword>switch antipsychotic</keyword>
	<keyword>schizoaffective disorder</keyword>
	<keyword>Risperdal</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>olanzapine</keyword>
	<keyword>Zyprexa</keyword>
</DOC>